[go: up one dir, main page]

PL2625180T3 - Leczenie chorób neurodegeneracyjnych związkami porfirynowymi - Google Patents

Leczenie chorób neurodegeneracyjnych związkami porfirynowymi

Info

Publication number
PL2625180T3
PL2625180T3 PL11831640.5T PL11831640T PL2625180T3 PL 2625180 T3 PL2625180 T3 PL 2625180T3 PL 11831640 T PL11831640 T PL 11831640T PL 2625180 T3 PL2625180 T3 PL 2625180T3
Authority
PL
Poland
Prior art keywords
neurodegenerative diseases
porphyrin
treatment
porphyrin treatment
neurodegenerative
Prior art date
Application number
PL11831640.5T
Other languages
English (en)
Inventor
Manisha Patel
Brian Day
John Mcmanus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2625180T3 publication Critical patent/PL2625180T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL11831640.5T 2010-10-06 2011-10-06 Leczenie chorób neurodegeneracyjnych związkami porfirynowymi PL2625180T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39027010P 2010-10-06 2010-10-06

Publications (1)

Publication Number Publication Date
PL2625180T3 true PL2625180T3 (pl) 2016-10-31

Family

ID=45928446

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11831640.5T PL2625180T3 (pl) 2010-10-06 2011-10-06 Leczenie chorób neurodegeneracyjnych związkami porfirynowymi

Country Status (19)

Country Link
US (1) US20130225545A1 (pl)
EP (1) EP2625180B1 (pl)
JP (1) JP5908485B2 (pl)
KR (1) KR101932149B1 (pl)
AU (1) AU2011311903B2 (pl)
CA (1) CA2813570A1 (pl)
DK (1) DK2625180T3 (pl)
ES (1) ES2574789T3 (pl)
HR (1) HRP20160514T1 (pl)
HU (1) HUE029083T2 (pl)
IL (1) IL225624A (pl)
LT (1) LT2625180T (pl)
NZ (1) NZ609924A (pl)
PL (1) PL2625180T3 (pl)
PT (1) PT2625180E (pl)
RS (1) RS54911B1 (pl)
SI (1) SI2625180T1 (pl)
SM (1) SMT201600196B (pl)
WO (1) WO2012048164A2 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1200728A1 (en) 2011-12-02 2015-08-14 科罗拉多大学董事会,法人团体 Metalloporphyrin neurological treatments
WO2016168343A1 (en) * 2015-04-13 2016-10-20 National Jewish Health Thiocyanate salts for anti-inflammation
KR20250079633A (ko) 2023-11-27 2025-06-04 서울대학교산학협력단 체내 주입형 하이드로겔 및 그 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571908A (en) * 1987-01-02 1996-11-05 Sun Company, Inc. (R&M) Porphyrins
CA2309154C (en) * 1997-11-03 2010-02-16 Duke University Substituted porphyrins
AU771259B2 (en) * 1998-04-24 2004-03-18 Aeolus Sciences, Inc. Substituted porphyrins
US6632808B1 (en) * 1998-08-11 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of amyloid formation
ATE552260T1 (de) * 1999-01-25 2012-04-15 Nat Jewish Health Substituierte porphyrine und deren therapeutische verwendung
WO2003006426A1 (en) * 2001-07-13 2003-01-23 Axxima Pharmaceuticals Ag Aromatic guanylhydrazones as effective compounds against neurodiseases
WO2005000854A2 (en) * 2003-06-06 2005-01-06 Eukarion, Inc. Orally bioavailable low molecular weight metalloporphyrins as antioxidants
GB0415663D0 (en) * 2004-07-13 2004-08-18 Psimei Pharmaceuticals Plc Compound
JP2009298731A (ja) * 2008-06-13 2009-12-24 Tokyo Metropolitan Univ 酸化傷害を抑制する金属ポルフィリン錯体、及びそれを用いた医薬組成物
US20120289492A1 (en) * 2009-09-02 2012-11-15 The Regents Of The University Of Colorado, A Body Corporate Methods of treating mitochondrial disorders using metalloporphyrins

Also Published As

Publication number Publication date
JP2013542936A (ja) 2013-11-28
HUE029083T2 (en) 2017-02-28
IL225624A (en) 2017-11-30
CA2813570A1 (en) 2012-04-12
ES2574789T3 (es) 2016-06-22
IL225624A0 (en) 2013-06-27
AU2011311903B2 (en) 2016-11-17
HRP20160514T1 (hr) 2016-09-23
WO2012048164A2 (en) 2012-04-12
DK2625180T3 (en) 2016-06-06
LT2625180T (lt) 2016-09-12
NZ609924A (en) 2015-02-27
PT2625180E (pt) 2016-06-07
EP2625180A2 (en) 2013-08-14
AU2011311903A1 (en) 2013-05-23
JP5908485B2 (ja) 2016-05-11
SI2625180T1 (sl) 2016-08-31
US20130225545A1 (en) 2013-08-29
WO2012048164A3 (en) 2012-07-19
SMT201600196B (it) 2016-08-31
KR101932149B1 (ko) 2018-12-26
KR20130115275A (ko) 2013-10-21
EP2625180A4 (en) 2014-05-14
RS54911B1 (sr) 2016-10-31
EP2625180B1 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
ZA201301601B (en) Treatment of diseases
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
ZA201402424B (en) 1- arylcarbonyl -4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
IL232530A0 (en) Combined cancer treatment
SG10201508495VA (en) Combination treatment of cancer
EP2611765A4 (en) METHODS OF TREATING NEURODEGENERATIVE DISEASES
IL228430A0 (en) Cancer treatment
IL256026B (en) Treatment methods
ZA201208389B (en) Treatment of proliferative diseases
PL2625180T3 (pl) Leczenie chorób neurodegeneracyjnych związkami porfirynowymi
IL228589A0 (en) Medical Care
IL222690A0 (en) Treatment of autoimmune diseases
GB201317550D0 (en) Use of Enalaprilat for treatment of neurodegenerative diseases
GB201017354D0 (en) Treatment of cancer
ZA201008686B (en) Treatment of animals
GB201017356D0 (en) Combination treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
GB201121783D0 (en) Treatment of cancer